Our study aims to analyse the presence of antibodies against NF155, ANO2 and FLOT-1/2 complex in our multiple sclerosis cohort, and to analyse if there are clinical features associated with these autoantibodies that could suggest that patients harbouring any of these antibodies constitute a differentiated multiple sclerosis subset. Here, FLOT1 is linked to multiple sclerosis.